MYC and breast cancer: One possible explanation for these seemingly contradictory findings is that a PIK3CA mutation may be an oncogenic driver event in early or low grade breast cancer development; while TP53 and MYC amplification are the oncogenic drivers that occur in a higher grade or a later stage breast cancer.